Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc., a Delaware corporation, on May 22, 2025. The report details the entry into a material definitive agreement to establish an equity financing program. The Company is an emerging growth company with its principal executive offices in San Antonio, Texas.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to the new financing arrangement:
- Agreement Type: At-The-Market (ATM) Issuance Sales Agreement.
- Counterparty: WallachBeth Capital LLC (Sales Agent).
- Securities Offered: Common Stock, par value $0.007 per share (Symbol: BIAF).
- Maximum Aggregate Offering Value: $5,801,000 (based on Form S-3 limitations).
- Agent Compensation: 3.0% of the gross sales price of shares sold.
- Registration Basis: Shelf registration statement on Form S-3 (File No. 333-275608), declared effective November 27, 2023.
Material Changes and Operational Impact
The material change reported is the authorization of a flexible capital raising mechanism. The Company retains the right to set parameters for sales, including the number of shares, timing, daily volume limits, and minimum price thresholds. The Company has no obligation to sell any shares and may suspend the program at any time. The agreement may be terminated by either party upon 10 days' written notice or in the event of a material adverse change.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, earnings outlook, or management commentary regarding future operational performance. Key risks and contingencies associated with the ATM program include:
- Dilution: Future sales of common stock will dilute existing shareholders.
- Market Conditions: Sales are subject to prevailing market prices and may be suspended if market conditions are unfavorable.
- Costs: The Company will incur a 3.0% commission on gross proceeds and must reimburse certain specified expenses to the sales agent.
Investor Verification Checklist
- Verify the current trading price of BIAF to assess potential dilution impact relative to the $5.8 million cap.
- Review the full text of the At-The-Market Issuance Sales Agreement (Exhibit 1.1) for specific termination clauses and price limitations.
- Confirm the Company's current cash position and liquidity needs to understand the urgency of utilizing this facility.
- Check for any subsequent filings indicating the actual volume of shares sold under this agreement.